Dose-Response Relationships for Meningioma Radiosurgery. (December 2015)

• Record Type: Journal Article
• Authors: Sethi, Rajni A.; Rush, Stephen C.; Liu, Shian; Sethi, Suresh A.; Parker, Erik; Donahue, Bernadine; Narayana, Ashwatha; Silverman, Joshua; Kondziolka, Douglas; Golfinos, John G.
• Is Part Of: American journal of clinical oncology. Volume 38:Number 6(2015)
• Publication Date: 2015-12
• Subjects: atypical -- malignant -- meningioma -- radiosurgery -- dose-response; Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0000000000000008
• Languages: English
• ISSNs: 0277-3732

Abstract

Abstract : Objective: Dose-response relationships for meningioma radiosurgery are poorly characterized. We evaluated determinants of local recurrence for meningiomas treated with Gamma Knife radiosurgery (GKRS), to guide future treatment approaches to optimize tumor control. Materials and Methods: A total of 101 consecutive patients (108 tumors) who underwent GKRS for benign, atypical, or malignant meningiomas between 1998 and 2011 were studied. Local recurrence was assessed. Cox proportional hazards and logistic regression analyses were used to determine the association of patient-related, tumor-related, and treatment-related characteristics with local recurrence. Acute and late toxicity was evaluated. Results: World Health Organization (2007 classification) tumor grade was I (82%), II (11%), or III (7%). Median dose was 14 Gy (range, 10 to 18 Gy) for grade I tumors and 16 Gy (range, 12 to 20 Gy) for grade II and III tumors. Median follow-up was 25 months (maximum, 17 y). Two- /5-year actuarial local control rates were 100%/98% for grade I tumors and 76%/56% for grade II/III tumors. Higher tumor grade and lower GKRS dose were associated with local failure. In this cohort, there was a 42% relative reduction in local recurrence for each 1 Gy of dose escalation. Conclusions: Treatment was well tolerated with no moderate or severe toxicity. Tumor control was excellent in benign tumors and suboptimal in higher grade tumors. Because the main determinant of local recurrence was GKRS dose, we recommend dose escalation for atypical or malignant tumors to doses between 16 and 20 Gy where critical structures allow.